Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ:PCSA
Want to see PCSA full AI Analyst Report?
Top Page
Processa Pharmaceuticals
(NASDAQ:PCSA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▲(2400.00% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and substantial cash burn with a shrinking equity cushion). Technicals are mixed with some short-term improvement but ongoing longer-term weakness, while valuation offers limited support due to negative earnings and no dividend. A recent negative corporate event (expired licensing pact) adds incremental risk.
Positive Factors
Low leverage / zero debt
Zero reported debt materially reduces near-term refinancing and interest-rate exposure, giving management flexibility to prioritize R&D and partner talks rather than servicing borrowings. This durable balance-sheet feature lowers fixed financial obligations during clinical development stages.
Negative Factors
Heavy and persistent cash burn
Sustained negative operating and free cash flow at roughly -$15M TTM creates an ongoing funding requirement. Over a 2-6 month horizon this heightens reliance on external capital or partnerships, increasing dilution risk and potentially forcing discounted financings if clinical catalysts don't materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / zero debt
Zero reported debt materially reduces near-term refinancing and interest-rate exposure, giving management flexibility to prioritize R&D and partner talks rather than servicing borrowings. This durable balance-sheet feature lowers fixed financial obligations during clinical development stages.
Read all positive factors
Processa Pharmaceuticals (PCSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.56M
Dividend YieldN/A
Average Volume (3M)61.77K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue GrowthN/A
EPS Growth86.07%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.66
Shares Outstanding2,750,173
10 Day Avg. Volume66,566
30 Day Avg. Volume61,774
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.03K
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6
Revenue Forecast (FY)$10.01M
Processa Pharmaceuticals Business Overview & Revenue Model
Company Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tabl...
How the Company Makes Money
null...
Processa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -301.00 | -1.20K | 0.00 | 0.00 | -874.01K | 0.00 |
| EBITDA | -14.47M | -13.99M | -12.05M | -11.46M | -19.47M | -10.78M |
| Net Income | -14.11M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
Balance Sheet | ||||||
| Total Assets | 4.52M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.69M | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Total Debt | 0.00 | 0.00 | 73.51K | 150.55K | 229.45K | 78.46K |
| Total Liabilities | 1.98M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Stockholders Equity | 2.54M | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -12.25M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Operating Cash Flow | -12.25M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Investing Cash Flow | -1.35M | -850.00K | -3.24K | -2.78K | 0.00 | 0.00 |
| Financing Cash Flow | 12.39M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
Processa Pharmaceuticals Technical Analysis
Negative
0.12
Price Trends
2.77
Negative
2.79
Negative
4.61
Negative
Market Momentum
-0.01
Positive
45.68
Neutral
35.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 2.78, below the 50-day MA of 2.77, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.68 is Neutral, neither overbought nor oversold. The STOCH value of 35.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCSA.
Processa Pharmaceuticals Risk Analysis
Processa Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Processa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Processa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $16.27M | -1.51 | -94.94% | ― | ― | 53.06% | |
44 Neutral | $7.56M | -0.49 | -281.30% | ― | ― | 86.07% | |
44 Neutral | $18.22M | -3.70 | -66.69% | ― | -45.52% | -94.82% | |
41 Neutral | $7.32M | ― | ― | ― | ― | ― | |
40 Underperform | $6.06M | -1.06 | -246.04% | ― | ― | 54.48% | |
40 Underperform | $4.66M | -2.45 | -154.50% | ― | ― | 59.90% |
* Healthcare Sector Average
PCSA
Processa Pharmaceuticals
2.61
-3.42
-56.72%
CANF
Can-Fite BioPharma
3.46
-17.14
-83.20%
SNGX
Soligenix
0.39
-1.49
-79.41%
LPCN
Lipocine
2.24
-1.38
-38.12%
COCP
Cocrystal Pharma
1.11
-0.32
-22.38%
PHGE
BiomX
0.60
-9.48
-94.09%
Processa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Processa Pharmaceuticals Announces Transition of Chief Development Officer
Neutral
Apr 30, 2026
On April 30, 2026, Processa Pharmaceuticals approved a planned transition toward retirement for Dr. Sian Bigora, its Chief Development and Regulatory Officer. Effective May 1, 2026, she moved from a full-time executive officer role to a part-time ...
Business Operations and Strategy
Processa Ends PCS12852 Licensing Pact With Intact Therapeutics
Negative
Feb 19, 2026
On February 12, 2026, Processa Pharmaceuticals, Inc. reported that its Binding Term Sheet dated June 17, 2025 with Intact Therapeutics regarding the drug candidate PCS12852 had expired without the parties executing a definitive license agreement. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.